Equillium (EQ) Net Income (2018 - 2026)
Equillium (EQ) posted quarterly Net Income of -$15.9 million for Q1 2026, down 81.36% year-over-year from -$85.6 million in Q1 2025, and down 298.58% quarter-over-quarter from -$4.0 million in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Net Income (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Net Income for 9 consecutive years, with -$15.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 81.36% year-over-year to -$15.9 million; the TTM figure through Mar 2026 stood at -$34.8 million (down 145.52% YoY), while the FY2025 annual figure was -$22.4 million, down 176.31% from the prior year.
- Net Income retreated to -$15.9 million in Q1 2026 per EQ's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Net Income topped out at $17.9 million in Q4 2022 and bottomed at -$37.4 million in Q1 2022.
- Historically, Net Income has averaged -$6.7 million across 5 years, with a median of -$4.0 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income soared 272.09% — and 2025, when it plunged 124528.57%.
- Equillium's Net Income stood at $17.9 million in 2022, then plunged by 119.9% to -$3.6 million in 2023, then sank by 63.66% to -$5.8 million in 2024, then surged by 31.41% to -$4.0 million in 2025, then slumped by 298.58% to -$15.9 million in 2026.
- Business Quant data shows EQ's Net Income at -$15.9 million in Q1 2026, -$4.0 million in Q4 2025, and -$8.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -4.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.65 Mn |
| Mar 31, 2026 | -5.30 Mn |
| Dec 31, 2025 | -3.66 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.70 Mn |
| Dec 31, 2024 | -3.82 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 953,000.00 |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.98 Mn |
| Dec 31, 2022 | 15.88 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.76 Mn |
| Sep 30, 2021 | -10.12 Mn |